<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068272</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-02-2016</org_study_id>
    <nct_id>NCT04068272</nct_id>
  </id_info>
  <brief_title>Safety of Bosentan in Type II Diabetic Patients</brief_title>
  <acronym>BOSRET</acronym>
  <official_title>Masked, Placebo Controlled, Phase I Trial to Assess the Safety of Bosentan 5 mg/ml Ophthalmic Eyewash in Type II Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retinset SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Retinset SL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety of topical Bosentan in Type II Diabetes patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Phase I, masked, placebo controlled clinical trial to assess safety of topical
      Bosentan in Type II Diabetes patients with no diabetes retinopathy
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Covid 19 general restrictions in Spain - Will eventually be resumed
  </why_stopped>
  <start_date type="Actual">September 7, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1 Eye receives placebo, the other eye receives study drug. Eye elections is randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo and Study Drug have the same physical characteristics, labeling and packaging</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Epitheliopathy</measure>
    <time_frame>1 month</time_frame>
    <description>Presence of epitheliopathy in the cornea or conjunctiva</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of ocular discomfort</measure>
    <time_frame>1 month</time_frame>
    <description>Presence of ocular discomfort assessed with Ocular Surface Disease Index (OSDI) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior segment inflammation</measure>
    <time_frame>1 month</time_frame>
    <description>Presence of any sign of clinically significant inflammation at anterior segment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>Eyedrop</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent;

          -  Type II Diabetes Mellitus;

          -  18 or more years old

        Exclusion Criteria:

          -  Pregnant or breastfeeding Women

          -  Known allergy or intolerance to investigational product or any of its excipients

          -  Severe corneal abnormalities

          -  Any relevant ocular / ophthalmic pathology that may put study results at risk in the
             opinion of Principal Investigator

          -  Any sign or symptom of Diabetes Retinopathy

          -  Any ocular surgery in the 6 previous months to study inclusion

          -  Uncontrolled diabetes in the previous 3 months to inclusion or HbA1c levels ≥ 9% at
             baseline.

          -  Oxford Scale or OSDI scores compatible with study failure at inclusion visit. (Oxford
             ≥ 5 or OSTDI ≥ 13)

          -  Previous hepatopathy history or signs of hepatopathy at baseline.

          -  Contact lens use

          -  Actual treatment with the commercially available presentation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOBA</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

